PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
|Articles|June 28, 2011
A Conversation with NIH Director Francis S. Collins
Dr. Collins addresses NIH efforts to improve global healthcare, live from the BIO 2011 convention.
Advertisement
b
NIH's Francis S. Collins on Global Health Efforts and More
Director of the National Institutes of Health (NIH), Dr. Francis S. Collins, discusses NIH's efforts to improve global healthcare, including an update on the human genome project, a focus on infectious and rare diseases in the developing world, and R&D grants for small businesses. Podcast interview by Sr. Managing Editor Angie Drakulich, as part of the 2011 BIO Convention and BioVentures for Global Health Partnering for Global Health Forum.
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement